Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Stock Short Interest Report for October

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) saw a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 375,939 shares, an increase of 67.5% from the September 30th total of 224,403 shares. Based on an average daily volume of 168,469 shares, the short-interest ratio is presently 2.2 days. Approximately 3.0% of the shares of the company are short sold.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Susquehanna International Group LLP acquired a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at $63,000. BlackRock Inc. acquired a new position in shares of Tvardi Therapeutics during the second quarter valued at $181,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Tvardi Therapeutics during the second quarter valued at $34,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TVRD. Piper Sandler upgraded shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective for the company in a research note on Wednesday, July 8th. BTIG Research dropped their target price on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. UBS Group raised shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price for the company in a research report on Wednesday, July 8th. Lucid Cap Mkts raised shares of Tvardi Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.40.

Tvardi Therapeutics Price Performance

Shares of TVRD opened at $0.79 on Monday. The company has a market capitalization of $10.58 million, a P/E ratio of -0.28 and a beta of 0.37. Tvardi Therapeutics has a one year low of $0.77 and a one year high of $5.69. The business’s 50 day simple moving average is $1.38 and its 200-day simple moving average is $2.77.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, sell-side analysts anticipate that Tvardi Therapeutics will post -2.23 EPS for the current fiscal year.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development.

The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.